Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...

In 2025, CRISPR advanced gene editing with safe, effective therapies and AI tools, marking a shift towards real-world ...

The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...

D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, 4D ...

Seasoned Biotech Entrepreneur Dr. Christian Thirion Appointed CEO of DiNATEQ AG and Group Chief Strategy & Business Development Officer; Dr. Josef El Andari Named Chief Scientific Officer of DiNAQOR ...

NeuExcell Therapeutics announced encouraging clinical results of NXL-004, the world’s first in situ conversion gene therapy ...

Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...

The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the development of ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead ...

The treatment uses a modified, harmless virus to deliver healthy genes to a patient’s cells to treat genetic diseases. Read more at straitstimes.com. Read more at straitstimes.com.

Based on initial positive results from HOPE-B, etranacogene dezaparvovec became the first gene therapy approved for adults with hemophilia B who currently use factor IX prophylaxis therapy for blood ...

Nearly all adults carry Epstein–Barr virus—but new research reveals how it can hijack immune cells, sparking a chronic disease that attacks the body from within. This colorized transmission electron ...